Hereditary Angioedema Clinical Trial
— CHANGE 2Official title:
LEVP2006-1 CHANGE 2 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Safety/Efficacy Repeat Exposure Study of C1INH-nf (Human) in the Treatment of Acute HAE Attacks
Verified date | May 2021 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study objective was to evaluate the safety and efficacy of repeat use of C1INH-nf for the treatment of acute HAE attacks.
Status | Completed |
Enrollment | 113 |
Est. completion date | March 31, 2009 |
Est. primary completion date | March 31, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year and older |
Eligibility | Inclusion Criteria: This study was open to all subjects who: - Completed participation in LEVP2005-1/A (NCT00289211) and were not participating in LEVP2005-1/B (NCT01005888), any time after the 3-day telephone follow-up - Completed participation in LEVP2005-1/B any time after the final prophylactic therapy in Part B - Were enrolled but not randomized in LEVP2005-1/A after Part A was closed - Were excluded from LEVP2005-1 for any of the following reasons: - Pregnancy or lactation - Age less than 6 years - Narcotic addiction - Presence of anti-C1INH autoantibodies - Were not enrolled in LEVP2005-1 after enrollment in LEVP2005-1 was closed, under the following circumstances: - Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or - Had a known HAE-causing C1INH mutation, or - Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator Exclusion Criteria: - History of allergic reaction to C1INH or other blood products - Participated in any other investigational drug study within the past 30 days - Received blood or a blood product in the past 60 days other than C1INH-nf |
Country | Name | City | State |
---|---|---|---|
United States | Family Allergy and Asthma Center | Atlanta | Georgia |
United States | MeritCare Clinical Research | Bemidji | Minnesota |
United States | Allergy and Asthma Clinic of Northwest Arkansas | Bentonville | Arkansas |
United States | Montefiore Medical Center | Bronx | New York |
United States | Allergy & Asthma Centre of Dayton | Centerville | Ohio |
United States | AARA Research Center | Dallas | Texas |
United States | Welborn Clinic Allergy and Immunology | Evansville | Indiana |
United States | MeritCare Clinical Research | Fargo | North Dakota |
United States | Allergy and Asthma Center | Fort Lauderdale | Florida |
United States | University of Texas Medical Branch | Galveston | Texas |
United States | Allergy Partners of the Upstate | Greenville | South Carolina |
United States | Penn State University | Hershey | Pennsylvania |
United States | Baylor College of Medicine | Houston | Texas |
United States | Allergy Asthma and Dermatology Research Center | Lake Oswego | Oregon |
United States | Nevada Access to Research and Education Society | Las Vegas | Nevada |
United States | UCLA-David Geffen School of Medicine | Los Angeles | California |
United States | Winthrop University Hospital | Mineola | New York |
United States | Mount Sinai School of Medicine | New York | New York |
United States | UMDNJ Asthma and Allergy Research Center | Newark | New Jersey |
United States | Orlando Regional Healthcare | Orlando | Florida |
United States | Cornerstone Healthcare | Parkersburg | West Virginia |
United States | Allergy and Asthma Research Center | San Antonio | Texas |
United States | University of California, San Diego | San Diego | California |
United States | Allergy and Immunology Associates | Scottsdale | Arizona |
United States | Marycliff Allergy Specialists | Spokane | Washington |
United States | Grand Traverse Allergy | Traverse City | Michigan |
United States | Allergy Clinic of Tulsa | Tulsa | Oklahoma |
United States | Allergy and Asthma Clinical Research, Inc | Walnut Creek | California |
United States | Institute for Asthma and Allergy | Wheaton | Maryland |
United States | University of Massachusetts Medical School | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Shire |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Hereditary Angioedema (HAE) Attacks Treated With C1INH-nf | Duration of the study (2.5 years) | ||
Primary | Percent of HAE Attacks With Substantial Relief of the Defining Symptom | Subjects were to assess their symptoms every 15 minutes up to 4 hours after the initial dose or until substantial relief of the defining symptom was achieved. The conservative analysis defined substantial relief as 3 consecutive assessments of improvement of the defining symptom; any attack that did not have 3 consecutive documented reports of improvement was considered a treatment failure. In the less conservative analysis, attacks also were considered to have responded if clinical improvement of the defining symptom occurred but data were incomplete due to cessation of symptom assessments. | Within 4 hours after initial treatment | |
Secondary | Time to Beginning of Substantial Relief of the Defining Symptom | Subjects were to assess their symptoms every 15 minutes up to 4 hours after the initial dose or until substantial relief of the defining symptom was achieved. Substantial relief was defined as 3 consecutive assessments of improvement of the defining symptom. Beginning of substantial relief was considered the first of the 3 consecutive assessments. | Within 4 hours after initial treatment | |
Secondary | Time to Beginning of Substantial Relief of the Defining Symptom for Subjects Who Received Multiple Treatments | For attack number 1, the number of censored observations precluded estimation of the 95% confidence interval (CI) upper bound for median time to event (subjects who did not experience beginning of substantial relief of the defining symptom within 4 hours after initial treatment were included in the analysis as censored observations). Entry of 4.0 hours indicates that data were not estimable (NE); as non-numeric data are not supported by the 95% CI field, entry of the actual result (ie, NE or >4.0) was not possible. | Within 4 hours after initial treatment | |
Secondary | Antigenic C1 Inhibitor (C1INH) Serum Levels | Change in antigenic C1INH serum levels from pre-infusion to 1 hour after the initial dose of study drug. | Pre-infusion to 1 hour post-infusion | |
Secondary | Functional C1INH Serum Levels | Percent change in functional C1INH serum levels from pre-infusion to 1 hour after the initial dose of study drug. Functional C1INH serum levels are expressed as a percent of total detectable C1INH (ie, functional C1INH/total detectable C1INH). | Pre-infusion to 1 hour post-infusion | |
Secondary | Complement C4 Serum Levels | Change in complement C4 serum levels from pre-infusion to 1 hour after the initial dose of study drug. | Pre-infusion to 1 hour post-infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06007677 -
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
|
Phase 2 | |
Completed |
NCT00997204 -
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
|
Phase 3 | |
Completed |
NCT00748202 -
Berinert P Study of Subcutaneous Versus Intravenous Administration
|
Phase 3 | |
Completed |
NCT01426763 -
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
|
Phase 2 | |
Terminated |
NCT04091113 -
Hereditary Angioedema Kininogen Assay
|
||
Completed |
NCT00432510 -
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
|
Phase 1 | |
Completed |
NCT03712228 -
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
|
Phase 2 | |
Active, not recruiting |
NCT05453968 -
Berotralstat Treatment in Children With Hereditary Angioedema
|
Phase 3 | |
Recruiting |
NCT05511922 -
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
|
Phase 3 | |
Recruiting |
NCT05505916 -
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
|
Phase 3 | |
Completed |
NCT02303626 -
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02159430 -
Hereditary AngioEdema, Neurobiology and Psychopathology
|
N/A | |
Completed |
NCT01984788 -
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
|
Phase 2 | |
Completed |
NCT04888650 -
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
|
||
Completed |
NCT02448264 -
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
|
Phase 1 | |
Completed |
NCT05118958 -
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
|
Phase 1 | |
Completed |
NCT06414252 -
Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
|
||
Active, not recruiting |
NCT04739059 -
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
|
Phase 3 | |
Completed |
NCT02819102 -
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
|
Phase 1 | |
Completed |
NCT01679912 -
A Call Center During HAE Attacks (SOS HAE)
|
Phase 4 |